Delving into the Latest Updates on ALT-801 (Altor BioScience) with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

STAR-Ck

Target

IL-2R x p53

Action

antagonists, inhibitors

Mechanism

IL-2R antagonists(Interleukin-2 receptor antagonists), p53 inhibitors(Tumor protein p53 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Bladder CancerMultiple MyelomaAcute Myeloid Leukemia

Inactive Indication

Kidney NeoplasmsMetastatic melanomaMycosis Fungoides+ [4]

Originator Organization

Altor BioScience Corp.

Active Organization

National Cancer Institute

The University of Texas MD Anderson Cancer Center

Inactive Organization

Altor BioScience Corp.

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 19238030

This is a single-center open-label phase I clinical trial of delivering haploidentical natural killer (NK) cells matured ex vivo with ALT-801 followed by intravenous infusions of ALT-801 in patients with relapsed/refractory Acute Myeloid Leukemia (AML). The study will be conducted at M.D. Anderson Cancer Center (MDACC) and MDACC Children's Cancer Hospital in Houston, Texas.

Start Date01 Nov 2011

Sponsor / Collaborator

Altor BioScience Corp.

[+1]

NCT01029873

/ CompletedPhase 1/2

Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic profile of ALT-801 given with cisplatin in patients who are chemotherapy naïve and have metastatic melanoma that is considered surgically incurable. The anti-tumor responses of ALT-801 with cisplatin will also be assessed in this trial.

Start Date01 Feb 2010

Sponsor / Collaborator

Altor BioScience Corp.

[+1]

100 Clinical Results associated with ALT-801 (Altor BioScience)

Login to view more data

100 Translational Medicine associated with ALT-801 (Altor BioScience)

Login to view more data

100 Patents (Medical) associated with ALT-801 (Altor BioScience)

Login to view more data

2

Literatures (Medical) associated with ALT-801 (Altor BioScience)

01 Oct 2006·Clinical ImmunologyQ3 · MEDICINE

Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein

Q3 · MEDICINE

Article

Author: ShaMay Tang ; Jane Merrill ; Jeffrey L. Wong ; Xiaoyung Zhu ; Kai-ping Han ; Pierre-Andre Chavillaz ; Hing C. Wong ; Peter R. Rhode ; Hyung-il Lee ; Bai Liu ; Jinghai Wen ; Heather J. Belmont ; Kimberlyn F. Card ; Shari Price-Schiavi

We previously have generated a single-chain T cell receptor-cytokine fusion protein (264scTCR/IL-2) comprising interleukin-2 genetically linked to a soluble HLA-A2.1-restricted TCR recognizing a peptide of human p53 protein. In this report, we show that 264scTCR/IL-2 inhibits the growth of primary tumors derived from the A375 (p53+/HLA-A2.1+) human melanoma and exhibits significantly better antitumor activity than recombinant human IL-2 alone. Moreover, treatment with 264scTCR/IL-2 results in tumor growth retardation in mice bearing large A375 tumors and other p53+/HLA-A2.1+ human tumors but does not affect tumor outgrowth of HLA-A2.1-negative tumors. This suggests that antigen targeting plays a substantial role in the efficacy of 264scTCR/IL-2 against p53+/HLA-A2+ tumors. Further, the antitumor activity of 264scTCR/IL-2 was found to be likely mediated by NK cell activation and tumor infiltration. A biologically active chimeric version of the molecule (c264scTCR/IL-2) also exhibits favorable pharmacokinetic properties required of a clinical candidate for this novel class of potent antitumor activities and targeted anticancer immunotherapeutics.

01 Apr 2004·Cancer Immunology, ImmunotherapyQ2 · MEDICINE

A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity

Q2 · MEDICINE

Article

Author: John L. Francis ; Janette Builes ; Jon Weidanz ; Jin-an Jiao ; Ali Amirkhosravi ; Linda Sherman ; Hing C. Wong ; Javier Hernandez ; Heather Belmont ; Bai Liu ; Kimberlyn F. Card ; Elizabeth Thomson ; Shari A. Price-Schiavi ; Esperanza Nieves

Antibody-based targeted immunotherapy has shown promise as an approach to treat cancer. However, many known tumor-associated antigens are not expressed as integral membrane proteins and cannot be utilized as targets for antibody-based therapeutics. In order to expand the limited target range of antibodies, we have constructed a soluble single-chain T-cell receptor (TCR) fusion protein designated 264scTCR/IL-2. This fusion protein is comprised of a three-domain HLA-A2-restricted TCR specific for a peptide epitope of the human p53 tumor suppressor protein, which is overexpressed in a broad range of human malignancies. The 264scTCR/IL-2 fusion protein has been expressed at high levels in mammalian cells, and milligram quantities have been purified. MHC-restricted antigen-specific binding properties are maintained in the single-chain, three-domain TCR portion of the fusion protein, and the IL-2 portion retains bioactivity similar to that of free recombinant IL-2. Moreover, this fusion protein is capable of conjugating target and effector cells, remains intact in the blood and substantially increases the half life of the IL-2 portion of the molecule. Finally, the 264scTCR/IL-2 fusion protein can be used to stain tumor cells and is capable of reducing lung metastases in an experimental model of metastasis. Thus, TCR-based fusion proteins may provide a novel class of targeted immunotherapeutics for cancer.

100 Deals associated with ALT-801 (Altor BioScience)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15386

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 2	-	The University of Texas MD Anderson Cancer Center	-
Bladder Cancer	Phase 2	-	National Cancer Institute	-
Multiple Myeloma	Phase 2	-	National Cancer Institute	-
Multiple Myeloma	Phase 2	-	The University of Texas MD Anderson Cancer Center	-
Urogenital Neoplasms	Preclinical	United States	-	04 Jun 2011
Kidney Neoplasms	Preclinical	United States	Altor BioScience Corp.	01 Jun 2011
Mycosis Fungoides	Preclinical	United States	Altor BioScience Corp.	01 Jun 2011
Ureteral Neoplasms	Preclinical	United States	Altor BioScience Corp.	01 Jun 2011
Urethral Neoplasms	Preclinical	United States	Altor BioScience Corp.	01 Jun 2011
Metastatic melanoma	Preclinical	United States	Altor BioScience Corp.	01 Feb 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2012	Not Applicable	Metastatic melanoma	22	ALT-801+CDDP	(vnqzjgelev) = pwzdviakzv pdtgystyrw (lijtdogafa )	-	20 May 2012

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data